From: Toward population specific and personalized treatment of Helicobacter pylori infection
First-line Regimens | Dosing and frequencies |
---|---|
Clarithromycin triple therapy | A PPI bid, clarithromycin 500 mg bid, and amoxicillin 1 g bid or metronidazole 500 mg bid for 7–14 days |
Bismuth quadruple therapy | A PPI bid, bismuth qid, tetracycline 500 mg qid, and metronidazole 500 mg tid for 7–14 days |
Sequential therapy | A PPI bid plus amoxicillin 500 mg bid for 5–7 days, followed by a PPI bid plus clarithromycin 500 mg bid and metronidazole 500 mg bid for another 5–7 days |
Concomitant therapy | A PPI bid plus amoxicillin 500 mg bid, clarithromycin 500 mg bid and metronidazole 500 mg bid for 7–14 days |
Hybrid therapy | A PPI bid plus amoxicillin 500 mg bid for 5–7 days, followed by a PPI bid plus amoxicillin 500 mg bid, clarithromycin 500 mg bid and metronidazole 500 mg bid for another 5–7 days |
Second-line/ third regimens | |
 Levofloxacin triple therapy | A PPI bid, levofloxacin 500 mg qd, and amoxicillin 1 g bid for 10–14 days |
 Levofloxacin sequential therapy | A PPI bid plus amoxicillin 500 mg bid for 7 days, followed by a PPI bid plus levofloxacin 250 mg bid and metronidazole 500 mg bid for another 7 days |
 Levofloxacin concomitant therapy | A PPI bid plus amoxicillin 500 mg bid, levofloxacin 250 mg bid and metronidazole 500 mg bid for 7–14 days |
 Bismuth quadruple therapy | A PPI bid, bismuth qid, tetracycline 500 mg qid, and metronidazole 500 mg tid for 7–14 days |
Fourth-line regimen | |
 Rifabutin triple therapy | A PPI bid, rifabutin 150 mg bid, and amoxicillin 1 g bid for 14 days |